article thumbnail

Guest Blog: Reflecting on the 2024 Society of Toxicology of Canada Symposium, by Ria Falvo, Director, Reporting

Alta Sciences

Their passion and curiosity to expand the boundaries of toxicology research illuminated the room. As experts in early-phase drug development , from discovery through Phase II clinical research , we at Altasciences can share with STC members our accumulated knowledge and experience, and provide mentorship for future toxicologists.

article thumbnail

NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor

The Pharma Data

In addition, their collective research insights will greatly enhance existing efforts to translate the scientific potential of our AIM technology into therapies designed to address significant unmet patient needs.”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biomarkers: A Novel Approach to Understanding Dementia

PerkinElmer

Beyond the sheer breadth of patients involved, the project encompasses leading scientists from seven UK universities (Cambridge, Cardiff, Edinburgh, Imperial College London, Newcastle, University College London, and Swansea), non-profit associations, and various companies within the clinical research industry.

article thumbnail

Precision for Medicine Expands Advanced Tissue Profiling and Genomic Capabilities with new Houston Laboratory

Precision for Medicine

Additional expanded clinical research services at the Houston facility include: Expanded blood processing rooms Dedicated dark rooms for multiplex IHC staining, imaging, and flow cytometry Histotechnology capabilities Digital Pathology with artificial intelligence (AI) Dedicated clean rooms for genomics.

article thumbnail

AM-Pharma Appoints Chief Medical Officer and VP Manufacturing to Support Global Pivotal Trial in Sepsis-associated Acute Kidney Injury

The Pharma Data

in Cell Biology from Utrecht University. Earlier in his career, he held development and engineering positions at BAC, part of Life Technologies, Unilever, and Crucell. Dr. van de Laar holds a M.Sc. in Bioprocess Technology from Wageningen University and a Ph.D. About AM-Pharma.

Trials 40